Season 3 - Ep.3: Optimal management of angina - Artificial sweeteners and cardiovascular risk

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies

Optimal management of angina

Artificial sweeteners and cardiovascular risk

Statistics Made Easy: Network meta-analyses

Host: Perry Elliott

Guests: Carlos Aguiar, Christiaan Vrints, Marco Witkowski

Want to watch that episode? Go to: https://esc365.escardio.org/event/1793

Disclaimer

ESC TV Today is supported by Bristol Myers Squibb.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Antonio Greco, Nicolle Kraenkel, Christiaan Vrints and Marco Witkowski have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.